For many years, first (e.g., gefitinib and erlotinib) or second-generation (e.g., afatinib) EGFR TKIs have been used successfully as first-line therapy in advanced EGFR-mutated NSCLC [12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.